Ashland Q4 sales $522M (+1% YoY), adj. EBITDA $124M (+68%), issues FY2025 outlook

ASHLAND INC.

2024-FY EPS reported $3.36 revenue$2,113,000,000

Sales $522M, up 1% YoY; nutraceuticals divestiture and CMC/MC curtailments reduced sales ~$24M (5%).
Adjusted EBITDA $124M (+68% YoY); below expectations due to HEC startup issues (~$5M) and weak China coatings demand.
Net income $16M vs $(4)M; adjusted EPS ex-intangibles $1.26, up from $0.41 YoY.
Bought back 1.7M shares in Q4; $620M remains under evergreen authorization. Cash from ops $80M; ongoing FCF $88M.
Sold nutraceuticals to Turnspire Capital; production at U.S. cellulosic site normalized early October.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.